Roivant Sciences (United States)

Recent papers from Roivant Sciences (United States)

1. Semantic State Abstraction Interfaces for LLM-Augmented Portfolio Decisions: Multi-Axis News Decomposition and RL Diagnostics2026
2. Indiscrete Scalar Ontology: A Universal Framework for Scale-Relative Combination and Emergence2026
3. Human in vitro neuromuscular junction model to functionally dissect the pathogenic mechanism of anti-AChR autoantibody-positive myasthenia gravisBMC Pharmacology and Toxicology · 2025
4. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisJournal of the American Academy of Dermatology · 2025
5. Preclinical efficacy of a modified gamma-globin lentivirus gene therapy in Berkeley sickle cell anemia mice and human xenograft modelsMolecular Therapy — Methods & Clinical Development · 2025
6. Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trialsJournal of Dermatological Treatment · 2025
7. Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenDermatology and Therapy · 2025
8. Epidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims databaseBMJ Neurology Open · 2025
9. The Morahan Pediatric Concussion Exercise Tolerance Test (MPCETT): Assessing the Safety and Utility of Exercise Tolerance Testing in Children with Concussion Ages 6 to 12Clinical Journal of Sport Medicine · 2024
10. Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims DatabaseClinical Endocrinology · 2024
11. Pharmacotherapy of acute ST-elevation myocardial infarction and the pharmacist’s role, part 2: Complications, post-revascularization care, and quality improvementAmerican Journal of Health-System Pharmacy · 2024
12. p70S6K as a Potential Anti-COVID-19 Target: Insights from Wet Bench and In Silico StudiesCells · 2024
13. SP-101, a novel adeno-associated virus gene therapy for the treatment of cystic fibrosis, mediates functional correction of primary human airway epithelia from donors with cystic fibrosisHuman Gene Therapy · 2024
14. Inhalation of SP-101 followed by inhaled doxorubicin results in robust and durable hCFTRΔR transgene expression in the airways of wild-type and cystic fibrosis ferretsHuman Gene Therapy · 2024
15. 671 - Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitisBritish Journal of Dermatology · 2024
16. 670 - Tapinarof cream 1% once daily is efficacious for the treatment of atopic dermatitis in patients with skin of color down to 2 years of age in two pivotal phase 3 trialsBritish Journal of Dermatology · 2024
17. Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age in Two Pivotal Phase 3 TrialsSKIN The Journal of Cutaneous Medicine · 2024
18. Impact of nebulization versus metered-dose inhaler utilization on viral particle dispersion in patients with COVID-19Journal of Infection Prevention · 2024
19. STORMM: Structure and topology replica molecular mechanics for chemical simulationsThe Journal of Chemical Physics · 2024
20. Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathiesPLoS ONE · 2024